BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1637675)

  • 41. Autoradiographic localization of cholecystokinin (CCK) receptor expression during the development of azaserine-induced rat pancreatic carcinoma.
    Tsuei BJ; Povoski SP; Zhou W; Bell RH
    Pancreas; 1996 Nov; 13(4):401-6. PubMed ID: 8899801
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Temporal expression of the gastrin (CCK-B) receptor during azaserine-induced pancreatic carcinogenesis.
    Povoski SP; Zhou W; Longnecker DS; Bell RH
    Pancreas; 1993 Sep; 8(5):615-21. PubMed ID: 8302799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dietary modulation of azaserine-induced pancreatic carcinogenesis in the rat.
    Roebuck BD; Yager JD; Longnecker DS
    Cancer Res; 1981 Mar; 41(3):888-93. PubMed ID: 7459874
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histochemical studies on gamma-glutamyltranspeptidase activity of pancreatic acinar cell lesions induced by 4-hydroxyaminoquinoline 1-oxide and/or azaserine in rats.
    Murata Y; Denda A; Obara T; Yokose Y; Konishi Y
    Exp Pathol; 1987; 32(1):41-53. PubMed ID: 2889612
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the effect of lorglumide on pancreatic growth stimulated by camostate in rat and hamster.
    Douglas BR; Woutersen RA; Jansen JB; Rovati LC; Lamers CB
    Life Sci; 1990; 46(4):281-6. PubMed ID: 2304371
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cholinergic dependence of pancreatic response to cholecystokinin in rats and guinea pigs.
    Pozo MJ; Estévez MJ; Alcon S; Camello PJ; Pariente JA; Salido GM
    Gen Pharmacol; 1995 Jul; 26(4):843-50. PubMed ID: 7635259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carcinogen-induced lesions in the rat pancreas: effects of varying levels of essential fatty acid.
    Roebuck BD; Longnecker DS; Baumgartner KJ; Thron CD
    Cancer Res; 1985 Nov; 45(11 Pt 1):5252-6. PubMed ID: 3876880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early indicators of exocrine pancreas carcinogenesis produced by non-genotoxic agents.
    Woutersen RA; van Garderen-Hoetmer A; Lamers CB; Scherer E
    Mutat Res; 1991 Jun; 248(2):291-302. PubMed ID: 2046686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The effect of fasting and cholecystokinin stimulation on normal and neoplastic tissue in the rat pancreas.
    Daly JM; Oates PS; Morgan RG
    Tissue Cell; 1992; 24(5):625-33. PubMed ID: 1279837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition by galanin of experimental carcinogenesis induced by azaserine in rat pancreas.
    Iishi H; Tatsuta M; Baba M; Yano H; Iseki K; Uehara H; Nakaizumi A
    Int J Cancer; 1998 Jan; 75(3):396-9. PubMed ID: 9455800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Kinetics of induction and growth of putative precancerous acinar cell foci in azaserine-induced rat pancreas carcinogenesis.
    Bax J; Schippers-Gillissen C; Woutersen RA; Scherer E
    Carcinogenesis; 1990 Feb; 11(2):245-50. PubMed ID: 2137381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of hypergastrinemia on pancreatic carcinogenesis.
    McDonald JM; Longnecker DS; Bell RH
    Am J Surg; 2002 Apr; 183(4):441-4. PubMed ID: 11975934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of cholecystokinin receptor antagonist loxiglumide on rat exocrine pancreas.
    Nakano S; Tachibana I; Otsuki M
    Pancreas; 1994 Jul; 9(4):425-33. PubMed ID: 7937691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
    Makovec F; Bani M; Cereda R; Chisté R; Pacini MA; Revel L; Rovati LA; Rovati LC; Setnikar I
    Arzneimittelforschung; 1987 Nov; 37(11):1265-8. PubMed ID: 3440035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of a diet high in fish oil (MaxEPA) on the formation of micronucleated erythrocytes in blood and on the number of atypical acinar cell foci Induced in rat pancreas by azaserine.
    Appel MJ; Woutersen RA
    Nutr Cancer; 2003; 47(1):57-61. PubMed ID: 14769538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition by neurotensin of azaserine-induced carcinogenesis in rat pancreas.
    Tatsuta M; Iishi H; Baba M; Nakaizumi A
    Int J Cancer; 1991 Feb; 47(3):408-12. PubMed ID: 1993548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of orchiectomy and testosterone on the early stages of azaserine-induced pancreatic carcinogenesis in the rat.
    Lhoste EF; Roebuck BD; Stern JE; Longnecker DS
    Pancreas; 1987; 2(1):38-43. PubMed ID: 3494994
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New proglumide-analogue CCK receptor antagonists: very potent and selective for peripheral tissues.
    Niederau C; Niederau M; Williams JA; Grendell JH
    Am J Physiol; 1986 Jun; 250(6 Pt 1):G856-60. PubMed ID: 2424321
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Endogenous cholecystokinin, the major factor responsible for dietary protein-induced pancreatic growth.
    Morisset J; Guan D; Jurkowska G; Rivard N; Green GM
    Pancreas; 1992; 7(5):522-9. PubMed ID: 1381095
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine.
    Sumi C; Longnecker DS; Roebuck BD; Brinck-Johnsen T
    Cancer Res; 1989 May; 49(9):2332-6. PubMed ID: 2706621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.